Quick Answer
PharmaCyte Biotech, Inc. reported Cash And Cash Equivalents At Carrying Value of $15.17 million for the year ending 2025.
- PharmaCyte Biotech, Inc. showed a decrease of -69.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from PharmaCyte Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on August 11, 2025.
- XBRL data for this metric is available from 2010 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2010: $0.00 | Q1 2011: $3.6 thousand | Q3 2011: $83.1 thousand | Q4 2011: $14.5 thousand | Q1 2012: $39.1 thousand | Q2 2012: $15.7 thousand | Q3 2012: $24.3 thousand | Q4 2012: $22.7 thousand | Q1 2013: $33.3 thousand | Q2 2013: $199.3 thousand | Q3 2013: $206.0 thousand | Q4 2013: $396.6 thousand | Q1 2014: $864.9 thousand | Q2 2014: $3.62 million | Q4 2014: $1.16 million | Q1 2015: $958.8 thousand | Q3 2023: $74.66 million | Q4 2023: $73.43 million | Q1 2024: $61.21 million | Q3 2024: $32.64 million | Q4 2024: $20.84 million | Q1 2025: $16.38 million | Q2 2025: $15.17 million | Q3 2025: $13.18 million | Q4 2025: $15.41 million | Q1 2026: $20.17 million.
- Over the full 8 years of available data (2010 to 2025), PharmaCyte Biotech, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 2,118,917.2%.
- Historical annual values: Fiscal year 2025: $15.17 million | Fiscal year 2024: $50.18 million | Fiscal year 2023: $68.04 million | Fiscal year 2022: $85.40 million | Fiscal year 2013: $199.3 thousand | Fiscal year 2012: $15.7 thousand | Fiscal year 2011: $57.2 thousand | Fiscal year 2010: $716.00.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: